Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS - Free Report) - Cantor Fitzgerald decreased their FY2024 earnings per share (EPS) estimates for Marinus Pharmaceuticals in a report released on Tuesday, April 16th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biopharmaceutical company will earn ($2.32) per share for the year, down from their previous forecast of ($2.13). Cantor Fitzgerald currently has a "Overweight" rating and a $28.00 target price on the stock. The consensus estimate for Marinus Pharmaceuticals' current full-year earnings is ($2.37) per share.
MRNS has been the topic of several other research reports. Oppenheimer reissued a "market perform" rating and issued a $9.00 target price on shares of Marinus Pharmaceuticals in a report on Thursday, March 7th. HC Wainwright reissued a "buy" rating and issued a $27.00 target price on shares of Marinus Pharmaceuticals in a report on Tuesday. Royal Bank of Canada reissued a "sector perform" rating and issued a $3.00 target price (down previously from $24.00) on shares of Marinus Pharmaceuticals in a report on Monday. Robert W. Baird reaffirmed a "neutral" rating on shares of Marinus Pharmaceuticals in a research note on Tuesday. Finally, Truist Financial decreased their price objective on Marinus Pharmaceuticals from $25.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Marinus Pharmaceuticals has a consensus rating of "Hold" and a consensus price target of $16.07.
Check Out Our Latest Analysis on Marinus Pharmaceuticals
Marinus Pharmaceuticals Price Performance
Marinus Pharmaceuticals stock traded down $0.03 during trading hours on Thursday, hitting $1.41. The stock had a trading volume of 4,816,224 shares, compared to its average volume of 1,406,006. The company has a debt-to-equity ratio of 5.68, a current ratio of 4.07 and a quick ratio of 4.01. The stock has a market capitalization of $77.45 million, a price-to-earnings ratio of -0.54 and a beta of 0.91. Marinus Pharmaceuticals has a 1-year low of $1.11 and a 1-year high of $11.26. The stock's fifty day moving average is $8.55 and its two-hundred day moving average is $8.40.
Marinus Pharmaceuticals (NASDAQ:MRNS - Get Free Report) last announced its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.10). The business had revenue of $7.19 million for the quarter, compared to analyst estimates of $7.78 million. Marinus Pharmaceuticals had a negative return on equity of 269.75% and a negative net margin of 456.31%. During the same period in the prior year, the company earned ($0.76) EPS.
Hedge Funds Weigh In On Marinus Pharmaceuticals
Large investors have recently added to or reduced their stakes in the business. Eventide Asset Management LLC raised its holdings in shares of Marinus Pharmaceuticals by 42.8% in the 3rd quarter. Eventide Asset Management LLC now owns 4,529,997 shares of the biopharmaceutical company's stock worth $36,466,000 after purchasing an additional 1,356,800 shares during the period. Lion Point Capital LP grew its position in shares of Marinus Pharmaceuticals by 14.6% in the 4th quarter. Lion Point Capital LP now owns 4,222,648 shares of the biopharmaceutical company's stock worth $21,480,000 after acquiring an additional 538,026 shares in the last quarter. BlackRock Inc. grew its position in shares of Marinus Pharmaceuticals by 245.4% in the 2nd quarter. BlackRock Inc. now owns 3,897,770 shares of the biopharmaceutical company's stock worth $42,330,000 after acquiring an additional 2,769,357 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Marinus Pharmaceuticals by 1.3% in the 4th quarter. Franklin Resources Inc. now owns 3,833,955 shares of the biopharmaceutical company's stock worth $41,675,000 after acquiring an additional 49,589 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of Marinus Pharmaceuticals in the 4th quarter worth approximately $13,990,000. 98.80% of the stock is currently owned by hedge funds and other institutional investors.
About Marinus Pharmaceuticals
(
Get Free Report)
Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Recommended Stories
Before you consider Marinus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Marinus Pharmaceuticals wasn't on the list.
While Marinus Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
